All eyes are on healthcare giant McKesson as it prepares to report fourth-quarter results. With a history of revenue misses and a slowing growth rate, analysts and investors are keen to see if the company can deliver a positive surprise.
Globe Life (NYSE: GL) is set to report its fourth-quarter earnings after the market closes on Wednesday. With the insurance sector facing headwinds, investors are watching to see if the company can deliver growth that outpaces its recent history of revenue misses.
The adhesive and materials giant is expected to post modest revenue growth as investors gauge its resilience against a backdrop of uneven results from packaging industry peers.
Oaktree Specialty Lending (NASDAQ: OCSL) is scheduled to release its fourth-quarter financial results before the market opens on Wednesday. Analysts project a year-over-year revenue decline, continuing a trend observed in recent quarters. Here’s a detailed preview of what investors should watch for.
Bio-Techne prepares to report quarterly earnings against a backdrop of declining revenue projections and mixed performances from life sciences peers.
The fast-food giant prepares to release its quarterly results as analysts project moderated growth and investors weigh recent performance against sector peers.
Across India's villages and small towns, a new generation of workers is logging on after sunset to label the data that trains the world's most advanced AI systems. This quiet workforce, many of them women and first-generation graduates, is finding economic opportunity while reshaping global tech's supply chain.
Healthcare distribution giant Cencora (COR) is set to report quarterly earnings before Wednesday's market open. Analysts project steady revenue growth, but investor focus will be on guidance amid mixed performances from sector peers.
Reynolds Consumer Products (NASDAQ: REYN) is scheduled to release its fourth-quarter financial results before market open on Wednesday. Investors will be watching closely to see if the household goods maker can maintain its track record of outperforming expectations, even as analysts project a slight year-over-year revenue dip.
After Abbott Laboratories' stock plunged nearly 10% on disappointing revenue, CEO Robert B. Ford made a significant personal investment, purchasing $2 million in company shares. This move, seen as a strong signal of insider confidence, highlights a clash between short-term market jitters and long-term corporate strategy.
Twist Bioscience's proprietary silicon-based DNA manufacturing platform is driving double-digit revenue growth and margin expansion, positioning the synthetic biology tools provider on a clear path to adjusted EBITDA breakeven by fiscal 2026.
ASGN Inc. is set to report its fourth-quarter financial results after the bell on Wednesday, with Wall Street anticipating another year-over-year revenue decline. Investors will scrutinize the performance for signs of stabilization in a competitive sector.
Beyond the headlines of rocket launches, companies building the critical infrastructure for the orbital economy are gaining strategic importance. Redwire Corporation (NYSE: RDW), with its niche technologies powering everything from lunar missions to potential space-based data centers, presents a compelling, if complex, investment thesis in the burgeoning space sector.
A sophisticated, high-conviction options trade by a large investor signals strong confidence in Edwards Lifesciences' fundamentals, with a potential breakout eyed for early 2026 tied to regulatory milestones and sustained growth in its mitral valve business.
Amid a challenging home furnishings market, luxury retailer RH is posting resilient results and gaining ground on competitors. A closer look reveals a strategy pivoting on international expansion, high-margin experiential offerings, and disciplined inventory management, setting the stage for ambitious long-term growth.
French biotech Abivax sees renewed investor interest following strong Phase 3 data for its oral therapy obefazimod in hard-to-treat ulcerative colitis, with analysts pointing to a clear path to regulatory approval and significant market potential.
Despite near-term pressures in China and IP markets, Synopsys's robust recurring revenue, strategic Ansys acquisition, and pivotal role in AI-driven chip design are building a compelling case for investor confidence, backed by strong margin expansion and cash flow projections.
Cronos Group's stock has rallied on renewed optimism for U.S. cannabis reform. We examine the regulatory shift, strategic positioning, and long-term potential driving investor sentiment.
Since its separation from General Electric, GE Vernova has seen its stock surge nearly 400%, fueled by a powerful mix of steady cash flow from gas turbines and explosive growth in grid electrification. We examine the complex investment thesis behind this energy sector standout.
Venture Global LNG, a polarizing leader in U.S. gas export infrastructure, trades at a deep discount despite record operational performance. This analysis explores the bull case for the stock, which hinges on resolving multibillion-dollar legal disputes and capitalizing on soaring global LNG demand.
